{"id":"W4409822412","doi":"10.1158/1538-7445.am2025-ct032","title":"Abstract CT032: Phase 1/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC)","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Internal medicine; Oncology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009427089,0.001381005,0.001082501,0.0004152576,0.0003717569,0.0008881861,0.0007420619,0.001030037,0.008065966],"category_scores_gemma":[0.0005640185,0.0003545469,0.0009203912,0.000496753,0.0006353256,0.0006243251,0.0003160507,0.002314082,0.001488224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001201959,"about_ca_system_score_gemma":0.00161309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001936076,"about_ca_topic_score_gemma":0.00556455,"domain_scores_codex":[0.9997573,0.0001115111,0.00001390892,0.00003651786,0.00003019271,0.00005055769],"domain_scores_gemma":[0.9996903,0.0000405288,0.00005385682,0.00002562954,0.00002759094,0.0001620625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6811643,0.03948976,0.007989499,0.002185421,0.001603612,0.0004804815,0.0002445037,0.004877541,0.08818296,0.0007474718,0.02197564,0.1510588],"study_design_scores_gemma":[0.636029,0.3308116,0.01216635,0.0001164558,0.0005041535,0.0005920023,0.0000728458,0.002111994,0.01007098,0.0003390128,0.007142948,0.00004274247],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740101,0.004569716,0.001313071,0.001273131,0.0002173559,0.004904196,0.006242619,0.0004476529,0.00702218],"genre_scores_gemma":[0.9711335,0.002211303,0.002993196,0.001582259,0.0001646345,0.004874276,0.008554784,0.00008443646,0.008401593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008065966,"threshold_uncertainty_score":0.02698338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0508172791414621,"score_gpt":0.3877290178043117,"score_spread":0.3369117386628496,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}